Drug Profile
Filgrastim biosimilar - Amega Biotech
Alternative Names: G-CSF biosimilar - Amega Biotech; Recombinant filgrastim - Amega Biotech; Recombinant G-CSF - Amega BiotechLatest Information Update: 12 Nov 2021
Price :
$50
*
At a glance
- Originator Amega Biotech
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Acute myeloid leukaemia; Neutropenia
Most Recent Events
- 15 Aug 2013 Investigation in Acute myeloid leukaemia in Argentina (Parenteral)
- 15 Aug 2013 Investigation in Neutropenia in Argentina (Parenteral)